Antineoplastic Agents

This product is suitable for patients with unresectable hepatocellular carcinoma who have not previously received systemic therapy.The pivotal study of lenvatinib mesylate excluded patients with HCC amenable to local therapy, for whom no study data are available. 

Our products include: • Atosiban • Cabazitaxel • Cebrium® • Cerebrolysin® • Dacepton® • Dexmedetomidine • Docetaxel • Fulvestrant • MemoProve® • Oxytocin • Paclitaxel • Pemetrexed • Tachyben® • Terlipressin

• Paclitaxel (Package : Up to 500g Per request) • Pemetrexed (Package : Up to 1kg Per request) • Bortezomib (Package : Up to 40g Per request)

Cytopharma is the first pharmaceutical company in Africa & Middle East region entirely specialized in the development, manufacturing and marketing of high quality and affordable generic cytotoxic drugs. Established in Tunisia since 2011, Cytopharma purpose is to provide high quality and affordable...

under Development

As a cornerstone drug for the treatment of multiple myeloma, Bortezomib is used throughout the induction, consolidation and maintenance therapies for myeloma. In 2020, Bortezomib was recommended as a first-line drug for the full management of multiple myeloma in the Guidelines for Diagnosis and Treatm...

• Cytotoxic Injection (Liquid , Lyophilized) • ONCOLOGY  • CYTOTOXIC API • EU GMP  • JGMP (Japan) • KGMP (Korea) • PIC/S

Composition: Pemetrexed 100 mg & 500 mg

Indication: The treatment of malignant pleural mesothelioma & non-small cell lung cancer

Packed in : Dry vial 100 mg & 500 mg

Composition: Bortezomib 3.5 mg

Indication: 
The treatment of multiple myeloma patients who have received at least 1 prior therapy and have demonstrated disease progression on the last therapy. 

Packed in : Dry vial 3.5 mg